Skip to main content Accessibility help
  • Print publication year: 2015
  • Online publication date: August 2015

10 - Stroke and patent foramen ovale: the conundrum of closure

Related content

Powered by UNSILO
1.Hagen, PT, Scholz, DG, Edwards, WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984;59:1720.
2.Lechat, P, Mas, JL, Lascault, G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;38:1148–52.
3.Mas, J-L, Arquizan, C, Lamy, C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001;345:1740–6.
4.Homma, S, Di Tullio, MR, Sacco, RL, et al. Characteristics of patent foramen ovale associated with cryptogenic stroke: a biplane transesophageal echocardiographic study. Stroke 1994;25:582–6.
5.Furlan, AJ, Reisman, M, Massaro, J, et al. Closure of medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012;366:991–9.
6.Carroll, JD, Saver, JL, Thaler, DE, et al. Closure of patent foramen ovale after cryptogenic stroke. N Engl J Med 2013;368:1092–100.
7.Kernan, WN, Ovbiagele, B, Black, HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160–236.
8.Kearon, C, Kahn, SR, Agnelli, G, et al. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-based clinical practice guidelines (8th Edition). Chest 2008;133:454S545S.
9.Johnston, SC, Rothwell, PM, Nguyen-Huynh, MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007;369(9558):283–92.
10.Giardini, A, Donti, A, Formigari, R, et al. Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. Am J Cardiol 2004;94:1012–16.
11.Rajamani, K, Chaturvedi, S, Jin, Z, et al. Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events. The PICSS-APASS Study. Stroke 2009;40:2337–42.
12.Homma, S, Sacco, RL, Di Tullio, MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in cryptogenic stroke study. Circulation 2002;105:2625–31.
13.Meissner, I, Khandheria, BK, Heit, JA, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol 2006;47:4405.